Company: ATLCL
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001437749-25-025502
Chunk: 45

Company: Atlanticus Holdings Corp
Filing Date: 2025-08-07
Form: 10-Q
Item: Item 8
Chunk 45
---
 that we  may issue up to 500,000 shares of our common stock under the plan. Our Fourth Amended 2014 Plan provides that we  may grant equity awards representing up to 5,750,000 options on or shares of our common stock to members of our Board of Directors, employees, consultants and advisors. The Fourth Amended 2014 Plan was approved by our shareholders in  May 2019. As of  June 30, 2025, 40,197 shares remained available for issuance under the ESPP and 1,906,039 shares remained available for issuance under the Fourth Amended 2014 Plan.
    
   Exercises and vesting under our stock-based compensation plans resulted in no income tax-related charges to paid-in capital during the three and six months ended  June 30, 2025 and 2024.
    
   Restricted Stock and Restricted Stock Units
    
   During the three and six months ended  June 30, 2025 and 2024, we granted 65,411 shares, 74,414 shares, 3,007 shares and 209,636 shares of restricted stock and restricted stock units (net of any forfeitures), respectively, with aggregate grant date fair values of $3.4 million, $3.8 million, $0.1 million and $6.5 million, respectively. We incurred expenses of $0.9 million, $1.8 million, $1.0 million and $1.9 million during the three and six months ended  June 30, 2025 and 2024, respectively, related to restricted stock awards. When we grant restricted stock and restricted stock units, we defer the grant date value of the restricted stock and restricted stock unit and amortize that value (net of the value of anticipated forfeitures) as compensation expense with an offsetting entry to the paid-in capital component of our condensed consolidated shareholders’ equity. Our restricted stock awards typically vest over a range of 12 to 60 months (or other term as specified in the grant which  may include the achievement of performance measures) and are amortized to salaries and benefits expense ratably over applicable vesting periods. As of  June 30, 2025, our unamortized deferred compensation costs associated with non-vested restricted stock awards were $8.5 million with a weighted-average remaining amortization period of 3.2 years. No forfeitures